Q&A: BioCi­na’s new CEO Mark Wom­ack on the CD­MO he says is 'worth trav­el­ing over'

A hand­ful of CD­MOs have made changes at the top over the past few weeks, in­clud­ing Genezen and Cu­ria.

That al­so in­cludes Aus­tralian CD­MO BioCi­na, which an­nounced last week that Mark Wom­ack would be tak­ing the helm. Wom­ack pre­vi­ous­ly served as chief busi­ness of­fi­cer at AGC Bi­o­log­ics, CEO of In­di­an man­u­fac­tur­er Stelis Bio­phar­ma and most re­cent­ly, CEO at CD­MO KBI Bio­phar­ma and Se­lex­is SA.

BioCi­na com­plet­ed the takeover of a Pfiz­er man­u­fac­tur­ing fa­cil­i­ty in Ade­laide in 2021 and is now prep­ping for wider growth. End­points News sat down with Wom­ack to dis­cuss his new role, plans for the fu­ture, and how to com­pete in the wider CD­MO mar­ket. This in­ter­view has been edit­ed for brevi­ty and clar­i­ty.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN